KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Current Leases (2020 - 2025)

Recursion Pharmaceuticals' Current Leases history spans 6 years, with the latest figure at $12.7 million for Q4 2025.

  • For Q4 2025, Current Leases fell 8.21% year-over-year to $12.7 million; the TTM value through Dec 2025 reached $12.7 million, down 8.21%, while the annual FY2025 figure was $12.7 million, 8.21% down from the prior year.
  • Current Leases reached $12.7 million in Q4 2025 per RXRX's latest filing, up from $11.5 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $13.8 million in Q4 2024 to a low of $499000.0 in Q1 2021.
  • Average Current Leases over 5 years is $6.8 million, with a median of $6.0 million recorded in 2022.
  • Peak YoY movement for Current Leases: surged 950.5% in 2022, then dropped 8.21% in 2025.
  • A 5-year view of Current Leases shows it stood at $1.4 million in 2021, then soared by 320.34% to $6.0 million in 2022, then increased by 2.76% to $6.1 million in 2023, then skyrocketed by 125.56% to $13.8 million in 2024, then fell by 8.21% to $12.7 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Current Leases are $12.7 million (Q4 2025), $11.5 million (Q3 2025), and $11.7 million (Q2 2025).